Could a cocktail of leucine, sildenafil, and metformin tame hypertension?
NCT ID NCT07647003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether a fixed-dose combination of leucine, sildenafil, and metformin (NS-0200) can lower blood pressure in adults aged 18 to 75 with hypertension. About 150 participants receive one of two doses of the combination or a placebo for 12 weeks. The main goal is to see if the treatment reduces systolic blood pressure more than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NS-0200 (a combination of leucine, sildenafil, and metformin)
- What this could lead to
- If successful, this could offer a new oral treatment option for managing high blood pressure.
- What could go wrong
- This is an early Phase 2 study with a small number of participants, so results may not apply to everyone. The combination therapy may cause side effects or prove no better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we stop early artery aging in kids with kidney disease?
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control